Navigation Links
Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
Date:1/30/2008

BONITA SPRINGS, Fla., Jan. 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug (AFP-464) for the treatment of cancer. The first patient was dosed in December 2007 and enrollment is ongoing.

The primary objectives of the study are to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of AFP-464 in patients with advanced solid tumors. The trial is expected to enroll up to approximately 35 patients across two sites in Europe: Institut Gustave-Roussy, Villejuif, France and Jules Bordet Institute, Brussels, Belgium. Results from the trial are expected to be available in early 2009.

"We are delighted that dosing has begun in this important dose-escalation study of AFP-464 in patients with solid tumors," said Edmundo Muniz, Chief Executive Officer of Tigris. "AFP-464 is a first-in-class molecule with the potential to fill a large unmet medical need in the treatment of cancer. This first trial in Europe along with the two US Phase 1 trials provides us our first opportunity to assess the drug's activity in patients, and to further build on our understanding of the molecule's mechanism of action."

About AFP-464

AFP-464 is a novel anticancer agent currently being investigated in two phase 1 clinical trials sponsored by the National Cancer Institute ("NCI") in patients with solid tumors. Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound. In vivo antitumor activity of AFP-464 has been demonstrated in several xenograft studies in mice bearing renal and breast cancer.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV. Tigris is also developing three novel, targeted small molecule oncology compounds. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contact:

Anne White

Chief Operating Officer

Tigris Pharmaceuticals, Inc.

(239) 444-5400

info@tigrispharma.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
3. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
8. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
9. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
10. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 --> ... "Fetal (Labor & Delivery) and Neonatal Care Equipment Market ... Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - ... studies the global market over the forecast period of ... 6.28 Billion in 2015 and is poised to grow ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last week, ... of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA since ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) ... event in New York City on Thursday, January 21, 2016. Kingsley R. ... (both alumnus of the varsity Columbia soccer program) spoke at the event, offering ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):